News

Withdrawn AML drug back on market in US


 

Photo by Bill Branson

Vials of drug

The US Food and Drug Administration (FDA) has approved use of gemtuzumab ozogamicin (GO, Mylotarg), a treatment that was initially approved by the agency in 2000 but later pulled from the US market.

GO is an antibody-drug conjugate that consists of the cytotoxic agent calicheamicin attached to a monoclonal antibody targeting CD33.

GO is now approved to treat adults with newly diagnosed, CD33-positive acute myeloid leukemia (AML) and patients age 2 and older with CD33-positive, relapsed or refractory AML.

GO can be given alone or in combination with daunorubicin and cytarabine.

The prescribing information for GO includes a boxed warning detailing the risk of hepatotoxicity, including veno-occlusive disease or sinusoidal obstruction syndrome, associated with GO.

GO originates from a collaboration between Pfizer and Celltech, now UCB. Pfizer has sole responsibility for all manufacturing, clinical development, and commercialization activities for this molecule.

Market withdrawal and subsequent trials

GO was originally approved under the FDA’s accelerated approval program in 2000 for use as a single agent in patients with CD33-positive AML who had experienced their first relapse and were 60 years of age or older.

In 2010, Pfizer voluntarily withdrew GO from the US market due to the results of a confirmatory phase 3 trial, SWOG S0106.

This trial showed there was no clinical benefit for patients who received GO plus daunorubicin and cytarabine over patients who received only daunorubicin and cytarabine.

In addition, the rate of fatal, treatment-related toxicity was significantly higher in the GO arm of the study.

Because of the unmet need for effective treatments in AML, investigators expressed an interest in evaluating different doses and schedules of GO.

These independent investigators, with Pfizer’s support, conducted clinical trials that yielded more information on the efficacy and safety of GO.

The trials—ALFA-0701, AML-19, and MyloFrance-1—supported the new approval of GO. Updated data from these trials are included in the prescribing information, which is available for download at www.mylotarg.com.

Recommended Reading

Enasidenib data in IDH2-mutated AML are basis for combination therapy trials
MDedge Hematology and Oncology
FDA approves first gene therapy – tisagenlecleucel for ALL
MDedge Hematology and Oncology
FDA reapproves gemtuzumab ozogamicin for CD33-positive AML treatment
MDedge Hematology and Oncology
Young cancer patients want more digital support, survey says
MDedge Hematology and Oncology
Nanocarriers could treat leukemia, lymphoma and improve HSCT
MDedge Hematology and Oncology
FDA approves drug to treat CRS induced by CAR T-cell therapy
MDedge Hematology and Oncology
FDA approves first CAR T-cell therapy to treat ALL
MDedge Hematology and Oncology
TKI granted priority review for newly diagnosed CML
MDedge Hematology and Oncology
Bacterial infection inhibits hematopoiesis
MDedge Hematology and Oncology
High healthcare costs follow CCSs into adulthood
MDedge Hematology and Oncology